Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 5,353 matching trials from the live ClinicalTrials.gov search.
Conditions
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
Interventions
Deramiocel (CAP-1002), Placebo
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
10 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
Conditions
Hypertension, Stroke
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
30 Years and older
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more
Completed Phase 4 Interventional Results available

Oral Challenge in the Pediatric ED

NCT03404804
Conditions
Penicillin Allergy, Pediatric Emergency Medicine
Interventions
Amoxicillin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 16 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Heart Failure
Interventions
Observational
Other
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more
Conditions
Kidney Stone, Nephrolithiasis
Interventions
Ureteroscopy, Percutaneous Nephrolithotomy, Shock Wave Lithotripsy
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
1,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 24 more
Conditions
Cystic Fibrosis
Interventions
Cysteamine, Placebo Oral Capsule
Drug
Lead sponsor
NovaBiotics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes

NCT07228208
Conditions
Type 2 Diabetes (T2DM), Endothelial Dysfunction
Interventions
MitoQ (mitoquinol mesylate), Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Severe Acute Alcoholic Hepatitis
Interventions
ELAD, Standard of Care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more
Conditions
Depressive Disorder
Interventions
orvepitant, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 23 more
Conditions
Urinary Bladder Neoplasms
Interventions
Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
24
States / cities
Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
Conditions
Diabetes, Hyperlipidemia, Hypertension, Cardiovascular Disease
Interventions
CVRS Intervention
Behavioral
Lead sponsor
Korey Kennelty
Other
Eligibility
55 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
18
States / cities
Gainesville, Florida • Tampa, Florida • Pocatello, Idaho + 14 more
Conditions
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
1,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
Conditions
Type 2 Diabetes
Interventions
tesaglitazar
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 55 more
Completed Not applicable Interventional Results available

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

NCT02439749
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
30
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Conditions
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
Interventions
Lenalidomide, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Conditions
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions
Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 29 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
111
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more
Conditions
Right-To-Left Shunt
Interventions
Agitated Saline SoC, ASI-02
Drug
Lead sponsor
Agitated Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more
Conditions
Myasthenia Gravis
Interventions
thymectomy plus prednisone, prednisone alone
Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Completed Phase 2 Interventional Results available

Phase II HDM-SPIRE Safety and Efficacy Study

NCT02150343
Conditions
Rhinoconjunctivitis
Interventions
HDM-SPIRE, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 53 more
Conditions
Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions
Zoenasa-1:4, Mesalamine Enema
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more
Conditions
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Tafasitamab, Tazemetostat, Zanubrutinib
Procedure · Drug · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
104
States / cities
Tucson, Arizona • Beverly Hills, California • Duarte, California + 81 more
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
6,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
107
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
LINX device
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Englewood, Colorado + 16 more